Semaglutide Wegovy / Ozempic Mechanism: GLP-1 receptor agonist (single target) Weight loss: ~15-17% body weight (STEP trials, 68 weeks) Dosing: Weekly injection, titrated from 0.25mg to 2.4mg Common side effects: Nausea, vomiting, diarrhea, constipation (typically transient) Availability: Longer track record, more widely available Cardiovascular data: SELECT trial demonstrated 20% reduction in major cardiovascular events Tirzepatide Zepbound / Mounjaro Mechanism: Dual GLP-1 + GIP receptor agonist (two targets) Weight loss: ~20-22% body weight (SURMOUNT trials, 72 weeks) Dosing: Weekly injection, titrated from 2.5mg to 15mg Common side effects: Similar GI profile to semaglutide
In addition to accelerating fat break down and boosting your metabolism, this potent formula supports the production of collagen, which plays a vital part in the skins elasticity and firmness helping to reduce the appearance of cellulite
To ensure temporality between GLP-1 RA use and SUD onset, we established the observation window from January 1, 2005 (the year of initial GLP-1 RA approval) to February 24, 2025, based on the most recent data available from the AoU dataset
B.TranT
Visual Format: Approved vs investigational status map Key Labels: Cosmetic product, compounded peptide, non-injectable route, injectable route, FDA safety concern, approved drug label, regulatory standards, product category Suggested Layout: Use a horizontal status map with four blocks: Cosmetic context, Non-injectable compounding review, Injectable safety concern, and Approved drug labeling. Add a note that product category changes evidence and safety interpretation
